Logo image of NTLA

INTELLIA THERAPEUTICS INC (NTLA) Stock Fundamental Analysis

NASDAQ:NTLA - Nasdaq - US45826J1051 - Common Stock - Currency: USD

8.2  -0.28 (-3.3%)

After market: 8.27 +0.07 (+0.85%)

Fundamental Rating

3

Overall NTLA gets a fundamental rating of 3 out of 10. We evaluated NTLA against 566 industry peers in the Biotechnology industry. NTLA has a great financial health rating, but its profitability evaluates not so good. NTLA is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year NTLA has reported negative net income.
NTLA had a negative operating cash flow in the past year.
In the past 5 years NTLA always reported negative net income.
In the past 5 years NTLA always reported negative operating cash flow.
NTLA Yearly Net Income VS EBIT VS OCF VS FCFNTLA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100M -200M -300M -400M -500M

1.2 Ratios

NTLA has a Return On Assets of -43.58%. This is comparable to the rest of the industry: NTLA outperforms 52.83% of its industry peers.
NTLA has a Return On Equity (-59.52%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -43.58%
ROE -59.52%
ROIC N/A
ROA(3y)-37.25%
ROA(5y)-30.46%
ROE(3y)-47.91%
ROE(5y)-38.99%
ROIC(3y)N/A
ROIC(5y)N/A
NTLA Yearly ROA, ROE, ROICNTLA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10 -20 -30 -40 -50

1.3 Margins

NTLA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NTLA Yearly Profit, Operating, Gross MarginsNTLA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -500 -1K

More info and screens

7

2. Health

2.1 Basic Checks

NTLA does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for NTLA has been increased compared to 1 year ago.
Compared to 5 years ago, NTLA has more shares outstanding
There is no outstanding debt for NTLA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
NTLA Yearly Shares OutstandingNTLA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
NTLA Yearly Total Debt VS Total AssetsNTLA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

Based on the Altman-Z score of -1.81, we must say that NTLA is in the distress zone and has some risk of bankruptcy.
NTLA has a Altman-Z score (-1.81) which is in line with its industry peers.
There is no outstanding debt for NTLA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.81
ROIC/WACCN/A
WACC9.95%
NTLA Yearly LT Debt VS Equity VS FCFNTLA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B

2.3 Liquidity

A Current Ratio of 5.77 indicates that NTLA has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 5.77, NTLA is in the better half of the industry, outperforming 62.01% of the companies in the same industry.
NTLA has a Quick Ratio of 5.77. This indicates that NTLA is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of NTLA (5.77) is better than 62.37% of its industry peers.
Industry RankSector Rank
Current Ratio 5.77
Quick Ratio 5.77
NTLA Yearly Current Assets VS Current LiabilitesNTLA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

5

3. Growth

3.1 Past

NTLA shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 2.96%.
Looking at the last year, NTLA shows a very negative growth in Revenue. The Revenue has decreased by -22.28% in the last year.
Measured over the past years, NTLA shows a small growth in Revenue. The Revenue has been growing by 6.07% on average per year.
EPS 1Y (TTM)2.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.01%
Revenue 1Y (TTM)-22.28%
Revenue growth 3Y20.53%
Revenue growth 5Y6.07%
Sales Q2Q%771.57%

3.2 Future

Based on estimates for the next years, NTLA will show a very strong growth in Earnings Per Share. The EPS will grow by 33.02% on average per year.
NTLA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 106.61% yearly.
EPS Next Y8.43%
EPS Next 2Y5.6%
EPS Next 3Y6.81%
EPS Next 5Y33.02%
Revenue Next Year-2.78%
Revenue Next 2Y-5.54%
Revenue Next 3Y96.65%
Revenue Next 5Y106.61%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
NTLA Yearly Revenue VS EstimatesNTLA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 1B 2B 3B
NTLA Yearly EPS VS EstimatesNTLA Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 -5 10 -10 15

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for NTLA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NTLA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NTLA Price Earnings VS Forward Price EarningsNTLA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NTLA Per share dataNTLA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 6 8

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y5.6%
EPS Next 3Y6.81%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for NTLA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INTELLIA THERAPEUTICS INC

NASDAQ:NTLA (4/29/2025, 8:25:56 PM)

After market: 8.27 +0.07 (+0.85%)

8.2

-0.28 (-3.3%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-27 2025-02-27/bmo
Earnings (Next)05-01 2025-05-01/bmo
Inst Owners92.53%
Inst Owner Change-0.46%
Ins Owners1.23%
Ins Owner Change1.52%
Market Cap848.86M
Analysts79.41
Price Target43.69 (432.8%)
Short Float %29.11%
Short Ratio7.85
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)5.73%
Min EPS beat(2)5.12%
Max EPS beat(2)6.34%
EPS beat(4)3
Avg EPS beat(4)2.73%
Min EPS beat(4)-20.94%
Max EPS beat(4)20.41%
EPS beat(8)6
Avg EPS beat(8)4.51%
EPS beat(12)8
Avg EPS beat(12)-4.18%
EPS beat(16)8
Avg EPS beat(16)-8.45%
Revenue beat(2)2
Avg Revenue beat(2)30.81%
Min Revenue beat(2)13.7%
Max Revenue beat(2)47.93%
Revenue beat(4)3
Avg Revenue beat(4)35.95%
Min Revenue beat(4)-64.41%
Max Revenue beat(4)146.59%
Revenue beat(8)5
Avg Revenue beat(8)4.81%
Revenue beat(12)9
Avg Revenue beat(12)12.15%
Revenue beat(16)10
Avg Revenue beat(16)6.12%
PT rev (1m)-6.4%
PT rev (3m)-27.61%
EPS NQ rev (1m)-0.51%
EPS NQ rev (3m)7.03%
EPS NY rev (1m)-1.16%
EPS NY rev (3m)14.16%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)33.18%
Revenue NY rev (1m)5.96%
Revenue NY rev (3m)-1.88%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 14.67
P/FCF N/A
P/OCF N/A
P/B 0.97
P/tB 0.97
EV/EBITDA N/A
EPS(TTM)-5.25
EYN/A
EPS(NY)-4.81
Fwd EYN/A
FCF(TTM)-3.43
FCFYN/A
OCF(TTM)-3.37
OCFYN/A
SpS0.56
BVpS8.42
TBVpS8.42
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -43.58%
ROE -59.52%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-37.25%
ROA(5y)-30.46%
ROE(3y)-47.91%
ROE(5y)-38.99%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 56.18%
Cap/Sales 9.98%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.77
Quick Ratio 5.77
Altman-Z -1.81
F-Score4
WACC9.95%
ROIC/WACCN/A
Cap/Depr(3y)130.37%
Cap/Depr(5y)126.64%
Cap/Sales(3y)24.85%
Cap/Sales(5y)23.87%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)2.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.01%
EPS Next Y8.43%
EPS Next 2Y5.6%
EPS Next 3Y6.81%
EPS Next 5Y33.02%
Revenue 1Y (TTM)-22.28%
Revenue growth 3Y20.53%
Revenue growth 5Y6.07%
Sales Q2Q%771.57%
Revenue Next Year-2.78%
Revenue Next 2Y-5.54%
Revenue Next 3Y96.65%
Revenue Next 5Y106.61%
EBIT growth 1Y40.02%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year6.09%
EBIT Next 3Y1.93%
EBIT Next 5Y27.04%
FCF growth 1Y13.09%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y11.47%
OCF growth 3YN/A
OCF growth 5YN/A